Curevo Vaccine Is A Clinical Stage Biotechnology Company Based In Washingtonfounded In 2018The Company Is Focused On Developing Next Generation Adjuvanted Subunit Vaccines Aimed At Preventing And Treating Infectious Diseasestheir Mission Emphasizes Safetysupplyand Efficacywith A Commitment To Creating Vaccines That Are Effectivewell Toleratedand Accessible Worldwide Curevo S Lead Product Is Crv 101A Subunit Zostershinglesvaccine That Has Completed Phase I Clinical Trialsthis Vaccine Has Shown A Promising Safety Profile And Induces Strong Immune Responseswith Elevated Antibody Levels Persisting One Year After Vaccinationthe Company Specializes In Non Mrna Adjuvanted Subunit Vaccineswhich Are Designed To Enhance Tolerability And Effectiveness Curevo Has Secured Significant Fundingincluding A $60 Million Series A Financing Round And An Additional $110 Million To Advance Their Shingles Vaccinethe Company Is Actively Seeking Partners And Investors To Support Its Clinical Development Effortswith A Multidisciplinary Team Of Expertscurevo Is Well Positioned To Address Unmet Medical Needs In The Vaccine Market
